NASDAQ · NBIX
Healthcare · Drug Manufacturers - Specialty & Generic
$156.49
Down-$5.67 (-3.62%)
Updated Aug 13, 2026, 8:15 PM
SID Score
6.6/10
Composite research score
Smart Money
58/100
Neutral
Price performance
1M range · 21 trading sessions · Daily adjusted prices
NBIX closed at $156.49 after 21 trading sessions, down 9.04% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 12, 2026 | $159.74 | $159.98 | $154.8575 | $156.49 | 2.09M |
| Aug 11, 2026 | $165.46 | $165.46 | $161.78 | $161.94 | 808.12K |
| Aug 10, 2026 | $161.52 | $165.15 | $161.52 | $164.92 | 935.23K |
| Aug 7, 2026 | $161.53 | $164.7599 | $159.68 | $163.41 | 971.01K |
| Aug 6, 2026 | $161.28 | $162.51 | $158.475 | $159.82 | 1.37M |
| Aug 5, 2026 | $168.55 | $168.55 | $161.30 | $161.50 | 1.29M |
| Aug 4, 2026 | $166.89 | $169.015 | $165.705 | $166.06 | 1.2M |
| Aug 3, 2026 | $166.25 | $170.8788 | $164.01 | $166.23 | 1.52M |
| Jul 31, 2026 | $184.34 | $185.55 | $164.56 | $166.80 | 4.58M |
| Jul 30, 2026 | $179.00 | $186.12 | $176.60 | $185.50 | 2.17M |
| Jul 29, 2026 | $182.00 | $183.50 | $180.00 | $180.79 | 1.07M |
| Jul 28, 2026 | $178.84 | $182.91 | $176.25 | $182.83 | 1.33M |
| Jul 27, 2026 | $176.46 | $179.15 | $176.00 | $176.41 | 1.05M |
| Jul 24, 2026 | $174.25 | $177.30 | $173.43 | $175.77 | 1.13M |
| Jul 23, 2026 | $170.6701 | $174.99 | $170.0045 | $174.15 | 1.1M |
| Jul 22, 2026 | $178.87 | $181.00 | $171.81 | $172.69 | 1.19M |
| Jul 21, 2026 | $174.77 | $179.05 | $174.10 | $179.05 | 1.31M |
| Jul 20, 2026 | $172.37 | $174.59 | $171.70 | $173.00 | 977.54K |
| Jul 17, 2026 | $169.77 | $172.57 | $169.26 | $170.88 | 929.82K |
| Jul 16, 2026 | $170.78 | $172.615 | $169.01 | $171.55 | 900.95K |
| Jul 15, 2026 | $172.04 | $173.115 | $169.44 | $172.05 | 878.5K |
The latest Smart Investors Daily articles mentioning NBIX.
NBIX research
Company profile and research snapshot.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 3, 2026 | Truist Securities | Buy | — |
| Aug 3, 2026 | Wedbush | Outperform | — |
| Aug 3, 2026 | Canaccord Genuity | Buy | — |
| Jul 31, 2026 | Cantor Fitzgerald | Overweight | — |
| Jul 31, 2026 | TD Cowen | Buy | — |
No generated briefing is available yet.
SeekingAlpha · Mar 3, 2026
Neurocrine Biosciences, Inc. (NBIX) TD Cowen 46th Annual Health Care Conference March 3, 2026 11:50 AM ESTCompany ParticipantsKyle Gano - CEO &...
Yahoo · Feb 24, 2026
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that members of the management team will participate at the following investor conferences:
ChartMill · Feb 24, 2026
Neurocrine Biosciences (NBIX) combines strong revenue growth, debt-free finances, and a bullish chart pattern, signaling a potential breakout for investors.
Benzinga · Feb 24, 2026
Wolfe Research analyst Rudy Li initiates coverage on Neurocrine Biosciences (NASDAQ:NBIX) with a Outperform rating and announces Price Target of $160.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning NBIX.
